Abstract
The growth and metastasis of solid tumors critically depends on their ability to develop their own blood supply, a process known as tumor angiogenesis. Over the past decade much work has been performed to understand this process, and modifying this process provides a key point of therapeutic intervention in the fight against cancer. This Review explores the development of anti-VEGF-based antiangiogenic therapies, of which there are currently three licensed for clinical use worldwide. Although originally anticipated to inhibit the growth of tumor vessels, the induction of vascular normalization caused by these approved agents has provided a novel means of effective delivery of known chemotherapeutic agents. The development of small molecules that target VEGF receptors has resulted in the generation of inhibitors with not only vascular activity but antitumor activity in certain cancers. This Review will address the current status of vascular-disrupting strategies, such as therapies designed to induce tumor collapse by selectively destroying existing tumor vessels. These therapies can be broadly divided into small-molecular-weight vascular-disrupting agents and ligand-directed approaches. We discuss the current status of development, drug mechanisms of actions, combination with conventional chemotherapy and radiotherapy, and potential future targets for therapeutic intervention.
Key Points
-
Blockade of VEGF signaling results in vascular normalization, and the use of bevacizumab, an anti-VEGF agent, is effective only when combined with chemotherapy
-
Small-molecular-weight VEGF receptor inhibitors such as sorafenib and sunitinib inhibit a range of receptor tyrosine kinases
-
Sorafenib and sunitinib cause vascular normalization and additionally target stromal cells and certain tumor-cell types; they are currently being used as monotherapies
-
Microtubule-disrupting agents selectively destroy the tumor vasculature, leading to hemorrhagic necrosis of the tumor
-
The distinctive tumor microenvironment results in the differential expression of cell-surface and extracellular matrix molecules; these distinctive expression profiles can be used for imaging and targeting therapeutics specifically to the tumor
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).
Duda, D. G., Jain, R. K. & Willett, C. G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25, 4033–4042 (2007).
Helmlinger, G., Yuan, F., Dellian, M. & Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3, 177–182 (1997).
Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464–478 (2007).
Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826–835 (2002).
Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999).
Burri, P. H., Hlushchuk, R. & Djonov, V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev. Dyn. 231, 474–488 (2004).
Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signaling—in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
Gille, H. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276, 3222–3230 (2001).
Petit, A. M. et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523–1530 (1997).
Reinmuth, N. et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239–1241 (2001).
Brekken, R. A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60, 5117–5124 (2000).
Gerber, H. P. & Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671–680 (2005).
Miller, K. D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799 (2005).
Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963–969 (1997).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788–1795 (2007).
Horowitz, J. R. et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 17, 2793–2800 (1997).
Riely, G. J & Miller, V. A. Vascular endothelial growth factor trap in non small cell lung cancer. Clin. Cancer Res. 13, s4623–s4627 (2007).
Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005).
Auguste, P., Lemiere, S., Larrieu-Laharque, F. & Bikfalvi, A. Molecular mechanisms of tumor vascularization. Crit. Rev. Oncol. Hematol. 54, 53–61 (2005).
Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373–398 (2000).
Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–979 (2005).
Lodish, M. B. & Stratakis, C.A. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev. Anticancer Ther. 8, 625–632 (2008).
Gilliland, D. G. & Griffin, J. D. Role of FLT3 in leukemia. Curr. Opin. Hematol. 9, 274–281 (2002).
Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
Gollob, J. A., Wilhelm, S., Carter, C. & Kelley, S. L. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33, 392–406 (2006).
Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174 (2008).
Herbst, R. S., Heymach, J. V., O'Reilly, M. S., Onn, A. & Ryan, A. J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs 16, 239–249 (2007).
Hanrahan, E. O. & Heymach, J. V. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin. Cancer Res. 13, s4617–e4622 (2007).
Abramsson, A., Lindblom, P. & Betsholtz, C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112, 1142–1151 (2003).
Taguchi, E., Nakamura, K., Miura, T., Shibuya, M. & Isoe, T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 99, 623–630 (2008).
Prat, A., Casado, E. & Cortés, J. New approaches in angiogenic targeting for colorectal cancer. World J. Gastroenterol. 13, 5857–5866 (2007).
Azad, N. S. et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709–3714 (2008).
Burrows, F. J. & Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl Acad. Sci. USA 90, 8996–9000 (1993).
Tozer, G. M., Kanthou, C. & Baguley, B. C. Disrupting tumor blood vessels. Nat. Rev. Cancer 5, 423–435 (2005).
Huminiecki, L. & Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796–1806 (2000).
Huminiecki, L., Gorn, M., Suchting, S., Poulsom, R. & Bicknell, R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79, 547–552 (2002).
Suchting, S., Heal, P., Tahtis, K., Stewart, L. M. & Bicknell, R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J. 19, 121–123 (2005).
Herbert, J. M., Stekel, D., Sanderson, S., Heath, V. L. & Bicknell, R. A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumor endothelial genes. BMC Genomics 9, 153 (2008).
Li, J. L. & Harris, A. L. The potential of new tumor endothelium-specific markers for the development of antivascular therapy. Cancer Cell 11, 478–481 (2007).
Seaman, S. et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11, 539–554 (2007).
Chi, J. T. et al. Endothelial cell diversity revealed by global expression profiling. Proc. Natl Acad. Sci. USA 100, 10623–10628 (2003).
Castronovo, V. et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol. Cell. Proteomics 5, 2083–2091 (2006).
Castronovo, V. et al. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 7, 1188–1196 (2007).
Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumors for tissue-specific therapy. Nature 429, 629–635 (2004).
Hynes, R. O. & Yamada, K. M. Fibronectins: multifunctional modular glycoproteins. J. Cell Biol. 95, 369–377 (1982).
Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337–2342 (1987).
Castellani, P. et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612–618 (1994).
Pini, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769–21776 (1998).
Neri, D. & Bicknell, R. Tumor vascular targeting. Nat. Rev. Cancer 5, 436–446 (2005).
Carnemolla, B. et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108, 1139–1148 (1989).
Santimaria, M. et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9, 571–579 (2003).
Brack, S. S., Silacci, M., Birchler, M. & Neri, D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res. 12, 3200–3208 (2006).
Carnemolla, B. et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am. J. Pathol. 154, 1345–1352 (1999).
Akabani, G. et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J. Nucl. Med. 46, 1042–1051 (2005).
Rizzieri, D. A. et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104, 642–648 (2004).
Dechantsreiter, M. A. et al. N.-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42, 3033–3040 (1999).
Eliceiri, B. P. & Cheresh, D. A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103, 1227–1230 (1999).
MacDonald, T. J. et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48, 151–157 (2001).
Reardon, D. A., Nabors, L. B., Stupp, R. & Mikkelsen, T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin. Investig. Drugs 17, 1225–1235 (2008).
He, J., Luster, T. A. & Thorpe, P. E. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin. Cancer Res. 13, 5211–5218 (2007).
Huang, X., Bennett, M. & Thorpe, P. E. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61, 1–11 (2004).
Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M. & Barcos, M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res. 3, 1031–1044 (1997).
Wakai, Y. et al. Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23). Jpn J. Cancer Res. 91, 1319–1325 (2000).
Ran, S., Downes, A. & Thorpe, P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132–6140 (2002).
Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).
Ghosh, A. & Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 91, 528–539 (2004).
Milowsky, M. I. et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 25, 540–547 (2007).
Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415–427 (2004).
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J. & Chatal, J. F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823–834 (2006).
Reardon, D. A., Zalutsky, M. R. & Bigner, D. D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7, 675–687 (2007).
Dark, G. G. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829–1834 (1997).
Lippert, J. W. 3rd. Vascular disrupting agents. Bioorg. Med. Chem. 15, 605–615 (2007).
Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002).
Hua, J. et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 23, 1433–1440 (2003).
Cai, S. X. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Patents Anticancer Drug Discov. 2, 79–101 (2007).
Mauer, A. M. et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 3, 631–636 (2008).
Siemann, D. W., Chaplin, D. J. & Horsmann, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491–2499 (2004).
Siemann, D. W. & Shi, W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 28, 2027–2031 (2008).
Beerepoot, L. V. et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol. 24, 1491–1498 (2006).
Cooney, M. M. et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 10, 96–100 (2004).
Rusnati, M. & Presta, M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr. Pharm. Des. 13, 2025–2044 (2007).
Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463–475 (2007).
Jain, R. K. & Xu, L. alphaPlGF: a new kid on the antiangiogenesis block. Cell 131, 443–445 (2007).
Yan, M. & Plowman, G. D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13, 7243–7246 (2007).
Larrivee, B. et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev. 21, 2433–2447 (2007).
Heroult, M., Schaffner, F. & Augustin, H. G. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp. Cell Res. 312, 642–650 (2006).
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Chow, L. Q & Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25, 884–896 (2007).
Sonpavde, G., Hutson, T. E. & Sternberg, C. N. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs 17, 253–261 (2008).
Rugo, H. S. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474–5483 (2005).
Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645–4655 (2002).
Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146–6153 (2008).
Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774–4782 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heath, V., Bicknell, R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6, 395–404 (2009). https://doi.org/10.1038/nrclinonc.2009.52
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.52
This article is cited by
-
Ultrasound and microbubble-mediated drug delivery and immunotherapy
Journal of Medical Ultrasonics (2022)
-
Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer
Nature Communications (2021)
-
Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro
Medical Oncology (2020)
-
Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Journal of Experimental & Clinical Cancer Research (2019)
-
Angiogenesis in pancreatic cancer: current research status and clinical implications
Angiogenesis (2019)